IL212064A - Use of pirfenidone for the preparation of a medicament for the treatment of patients with atypical liver function - Google Patents

Use of pirfenidone for the preparation of a medicament for the treatment of patients with atypical liver function

Info

Publication number: IL212064A
Authority: IL; Israel
Prior art keywords: pirfenidone; medicament; patients; preparation; treatment
Prior art date: 2008-11-10

Application number

IL212064A

Other languages

Hebrew (he)

Other versions

IL212064A0 (en

Original Assignee

Intermune Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-10

Filing date

2011-03-31

Publication date

2016-06-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41427890&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL212064(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-04-22 Priority claimed from US12/428,393 external-priority patent/US7566729B1/en

2011-03-31 Application filed by Intermune Inc filed Critical Intermune Inc

2011-06-30 Publication of IL212064A0 publication Critical patent/IL212064A0/en

2016-06-30 Publication of IL212064A publication Critical patent/IL212064A/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Virology (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Oncology (AREA)
Rheumatology (AREA)
Biotechnology (AREA)
Orthopedic Medicine & Surgery (AREA)
Tropical Medicine & Parasitology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Food Science & Technology (AREA)
Cell Biology (AREA)
Pathology (AREA)

IL212064A 2008-11-10 2011-03-31 Use of pirfenidone for the preparation of a medicament for the treatment of patients with atypical liver function IL212064A (en)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US11310708P	2008-11-10	2008-11-10
US12/428,393 US7566729B1 (en)	2008-11-10	2009-04-22	Modifying pirfenidone treatment for patients with atypical liver function
US48822809A	2009-06-19	2009-06-19
US22894309P	2009-07-27	2009-07-27
US12/553,292 US7635707B1 (en)	2008-11-10	2009-09-03	Pirfenidone treatment for patients with atypical liver function
PCT/US2009/063702 WO2010054294A1 (en)	2008-11-10	2009-11-09	Pirfenidone treatment for patients with atypical liver function

Publications (2)

Publication Number	Publication Date
IL212064A0 IL212064A0 (en)	2011-06-30
IL212064A true IL212064A (en)	2016-06-30

Family

ID=41427890

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL212064A IL212064A (en)	2008-11-10	2011-03-31	Use of pirfenidone for the preparation of a medicament for the treatment of patients with atypical liver function

Country Status (39)

Country	Link
US (9)	US7635707B1 (en)
EP (4)	EP2343070B1 (en)
JP (3)	JP2012508253A (en)
KR (1)	KR101699501B1 (en)
CN (1)	CN102209543A (en)
AP (1)	AP2011005740A0 (en)
AT (1)	ATE503480T1 (en)
AU (3)	AU2009313302B2 (en)
BR (1)	BRPI0921022A2 (en)
CA (2)	CA2709997C (en)
CL (1)	CL2011000966A1 (en)
CO (1)	CO6382132A2 (en)
CU (1)	CU20110100A7 (en)
CY (2)	CY1111595T1 (en)
DE (1)	DE602009000986D1 (en)
DK (2)	DK2191831T3 (en)
EA (1)	EA022482B1 (en)
EC (1)	ECSP11011039A (en)
ES (3)	ES2525543T3 (en)
GE (1)	GEP201706719B (en)
HK (3)	HK1145138A1 (en)
HR (2)	HRP20110478T1 (en)
IL (1)	IL212064A (en)
MA (1)	MA32880B1 (en)
ME (1)	ME01189B (en)
MX (1)	MX2011004904A (en)
MY (1)	MY159353A (en)
NI (1)	NI201100091A (en)
PE (1)	PE20110683A1 (en)
PL (2)	PL2343070T3 (en)
PT (2)	PT2343070E (en)
RS (2)	RS53721B1 (en)
SI (2)	SI2343070T1 (en)
SM (2)	SMT201100030B (en)
SV (1)	SV2011003897A (en)
TN (1)	TN2011000217A1 (en)
TW (2)	TWI419877B (en)
WO (1)	WO2010054294A1 (en)
ZA (1)	ZA201102411B (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102099036B (en)	2008-06-03	2015-05-27	英特芒尼公司	Compounds and methods for treating inflammatory and fibrotic disorders
US7635707B1 (en)	2008-11-10	2009-12-22	Intermune, Inc.	Pirfenidone treatment for patients with atypical liver function
AP2011005824A0 (en) *	2009-01-26	2011-08-31	Intermune Inc	Methods for treating acute myocardial infarctions and associated disorders.
US7816383B1 (en)	2009-12-04	2010-10-19	Intermune, Inc.	Methods of administering pirfenidone therapy
EP4059499A1 (en)	2011-01-31	2022-09-21	Avalyn Pharma Inc.	Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10105356B2 (en)	2011-01-31	2018-10-23	Avalyn Pharma Inc.	Aerosol pirfenidone and pyridone analog compounds and uses thereof
MX2011007675A (en)	2011-07-19	2012-07-11	Cell Therapy And Technology S A De C V	Process for manufacturing a pharmaceutical composition in a sustained-release tablet form containing pirfenidone and the application thereof in the regression of chronic renal failure, breast capsular contracture and liver fibrosis in humans.
US9136461B2 (en) *	2011-10-13	2015-09-15	Mitsui Chemicals, Inc.	Polymeric piezoelectric material and process for producing the same
WO2013109856A2 (en) *	2012-01-18	2013-07-25	Genentech, Inc.	Methods of using fgf19 modulators
MX346763B (en)	2012-03-28	2017-03-31	Cell Therapy And Tech S A De C V	Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne.
MX356551B (en)	2012-08-23	2018-06-04	Grupo Medifarma S A De C V Star	Antiseptic, antiseborrheic, exfoliating composition for getting rid of or preventing acne.
CA2819967C (en)	2012-08-31	2016-03-22	Intermune, Inc.	Use of pirfenidone concomitantly with ciprofloxacin
AR092742A1 (en)	2012-10-02	2015-04-29	Intermune Inc	ANTIFIBROTIC PYRIDINONES
EP2968292A4 (en) *	2013-03-15	2016-11-23	Intermune Inc	METHODS FOR IMPROVING MICROVASCULAR INTEGRITY
CA2936330C (en)	2014-01-10	2023-01-03	Genoa Pharmaceuticals Inc.	Aerosol pirfenidone and pyridone analog compounds and uses thereof
AU2015209324A1 (en) *	2014-01-24	2016-07-21	Auspex Pharmaceuticals, Inc.	Substituted N-Aryl pyridinones
AU2015236283B2 (en) *	2014-03-25	2020-05-07	Leading BioSciences, Inc.	Compositions for the treatment of autodigestion
CN110452216B (en)	2014-04-02	2022-08-26	英特穆恩公司	Anti-fibrotic pyridinones
CN114588154A (en)	2015-02-05	2022-06-07	纪念斯隆凯特林癌症中心	Compositions and methods for treating edema
MA41544A (en) *	2015-02-19	2017-12-26	Novartis Ag	PANOBINOSTAT DOSAGE FOR THE TREATMENT OF MULTIPLE MYELOMA
CN108289883A (en) *	2015-12-11	2018-07-17	豪夫迈·罗氏有限公司	Vismodegib and pirfenidone conjoint therapy
CA2937365C (en)	2016-03-29	2018-09-18	F. Hoffmann-La Roche Ag	Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
WO2018026442A1 (en) *	2016-08-01	2018-02-08	The Regents Of The University Of California	Small molecule inhibition for preventing or treating fibrotic diseases
MX364040B (en) *	2016-11-11	2019-04-11	Cell Therapy And Tech S A De C V	Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash).
US20190388407A1 (en)	2017-02-12	2019-12-26	Aiviva Biopharma, Inc.	Multikinase inhibitors of vegf and tfg beta and uses thereof
KR102448705B1 (en) *	2017-08-12	2022-09-28	아이비바 바이오파마, 인크.	Multikinase Inhibitors and Uses in Reproductive and Gastrointestinal Fibrosis
MX366086B (en)	2017-08-15	2019-06-27	Cell Therapy And Tech S A De C V	A semi-solid topical composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage.
CA3109703C (en) *	2018-08-15	2023-10-17	Aiviva Biopharma, Inc.	Multi-kinase inhibitors of vegf and tgf beta and uses thereof
WO2021057599A1 (en) *	2019-09-26	2021-04-01	深圳先进技术研究院	Application of pirfenidone in preparing medicament for preventing and treating rheumatoid arthritis
WO2021110805A1 (en)	2019-12-04	2021-06-10	Idorsia Pharmaceuticals Ltd	Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
EP4486326A1 (en)	2022-02-28	2025-01-08	Nuformix Technologies Limited	Compositions and methods for treatment of idiopathic pulmonary fibrosis

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1000828A (en)	1907-07-25	1911-08-15	Pierre Lorillard	Conveyer.
CA1049411A (en)	1972-12-18	1979-02-27	Affiliated Medical Research	N-substituted pyridone and general method for preparing pyridones
US4052509A (en)	1972-12-18	1977-10-04	Affiliated Medical Research, Inc.	Method for reducing serum uric acid levels
US4042699A (en)	1972-12-18	1977-08-16	Affiliated Medical Research, Inc.	Method for reducing serum glucose levels
CA1244894A (en)	1985-09-27	1988-11-15	William A. Cole	Low voltage class b amplifier with low value decoupling capacitors
JPH02215719A (en)	1989-02-15	1990-08-28	Yamauchi Akitomo	Agent for repairing fibrosing lesion tissue and preventing fibrosing lesion
US5518729A (en)	1989-11-22	1996-05-21	Margolin; Solomon B.	Compositions and methods for reparation and prevention of fibrotic lesions
US5716632A (en)	1989-11-22	1998-02-10	Margolin; Solomon B.	Compositions and methods for reparation and prevention of fibrotic lesions
US5310562A (en)	1989-11-22	1994-05-10	Margolin Solomon B	Composition and method for reparation and prevention of fibrotic lesions
US6294350B1 (en)	1997-06-05	2001-09-25	Dalhousie University	Methods for treating fibroproliferative diseases
US6956044B1 (en) *	2000-02-21	2005-10-18	Margolin Solomon B	Compositions and methods for treatment of epilepsy
SE0101762D0 (en)	2001-05-18	2001-05-18	Astrazeneca Ab	New use
ZA200407655B (en)	2002-04-10	2005-11-02	Applied Research Systems	Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease.
CA2496577A1 (en)	2002-08-28	2004-03-11	Intermune, Inc.	Combination therapy for treatment of fibrotic disorders
JP4542743B2 (en)	2002-12-26	2010-09-15	Ｋｄｌ株式会社	Solution pharmaceutical composition of pyridone derivatives
EP1599171A2 (en)	2003-02-28	2005-11-30	Intermune, Inc.	Combination therapy for treating alphavirus infection and liver fibrosis
US7250905B2 (en)	2003-04-09	2007-07-31	Mano Dorsey Judd	Virtual antenna technology (VAT) and applications
CN101052726A (en)	2003-05-09	2007-10-10	森托科尔公司	IL-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
CA2525647A1 (en)	2003-05-16	2005-02-24	Intermune, Inc.	Synthetic chemokine receptor ligands and methods of use thereof
WO2004103296A2 (en)	2003-05-16	2004-12-02	Intermune, Inc.	Methods of treating idiopathic pulmonary fibrosis
WO2005000227A2 (en)	2003-06-06	2005-01-06	Intermune, Inc.	Methods of treating tnf-mediated disorders
US20070053877A1 (en)	2003-08-21	2007-03-08	Intermune, Inc.	Methods of treating idiopathic pulmonary fibrosis
CN1266144C (en)	2003-09-01	2006-07-26	上海凯曼生物科技有限公司	Compound of flavonoid as well as application and dosage form of extract product of the compound
WO2005040758A2 (en) *	2003-10-24	2005-05-06	Intermune, Inc.	Use of pirfenidone in therapeutic regimens
WO2005044200A2 (en)	2003-11-05	2005-05-19	Centocor, Inc.	Methods and compositions for treating mcp-1 related pathologies
CN100358872C (en)	2003-11-14	2008-01-02	上海睿星基因技术有限公司	The derivatives of pyridone and use thereof
WO2005067963A1 (en)	2003-12-23	2005-07-28	Intermune, Inc.	Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
WO2005063186A1 (en) *	2003-12-30	2005-07-14	Council Of Scientific & Industrial Research	Herbal oro-dental care composition and process for preparing the same
CA2557724A1 (en)	2004-02-27	2005-10-06	Centocor, Inc.	Methods and compositions for treating il-13 related pathologies
US20070053845A1 (en)	2004-03-02	2007-03-08	Shiladitya Sengupta	Nanocell drug delivery system
WO2005110478A2 (en)	2004-04-13	2005-11-24	Intermune, Inc.	Combination therapy for treating fibrotic disorders
US20060037057A1 (en)	2004-05-24	2006-02-16	Sharp Laboratories Of America, Inc.	Method and system of enabling trick play modes using HTTP GET
US7597884B2 (en)	2004-08-09	2009-10-06	Alios Biopharma, Inc.	Hyperglycosylated polypeptide variants and methods of use
AR051444A1 (en)	2004-09-24	2007-01-17	Centocor Inc	PROTEINS DERIVED FROM IL-23P40 SPECIFIC IMMUNOGLOBULIN, COMPOSITIONS, EPITHOPES, METHODS AND USES
WO2006039631A2 (en)	2004-09-30	2006-04-13	Centocor, Inc.	Methods and compositions for treating renal cell carcinoma related pathologies
CA2583089A1 (en)	2004-10-05	2006-04-20	Bayer Schering Pharma Aktiengesellschaft	Tafi inhibitors and their use to treat pulmonary fibrosis
AU2005299354A1 (en)	2004-10-27	2006-05-04	Medimmune, Llc	Modulators of EphA2 and ephrina1 for the treatment of fibrosis-related disease
WO2006050058A2 (en)	2004-10-28	2006-05-11	The General Hospital Corporation	Methods of detection and therapy of inflamed tissues using immune modulation
US20070065359A1 (en)	2005-03-14	2007-03-22	Shiladitya Sengupta	Nanocells for diagnosis and treatment of diseases and disorders
WO2006105538A2 (en)	2005-03-31	2006-10-05	Centocor, Inc.	Methods and compositions for treating il-21 related pathologies
CN1846699A (en)	2005-04-13	2006-10-18	中南大学湘雅医院	Application of 1- (substituted phenyl) -5-methyl-2- (1H) pyridone (I) compound in preparing medicines for resisting fibrosis of other organs or fibrosis of tissues except renal interstitial fibrosis
WO2006130297A2 (en)	2005-04-29	2006-12-07	Celgene Corporation	Solid forms of 1-( 5-(ih-i , 2 , 4 -triazol- 5 -yl)(1h-indazol-3-yl))-3-(2-piperidylethoxy)benzene
MX2007014114A (en)	2005-05-10	2008-03-14	Intermune Inc	DERIVATIVES OF PIRIDONA TO MODULATE THE SYSTEM OF PROTEIN KINASE ACTIVATED BY STRESS.
US20090131312A1 (en)	2005-05-18	2009-05-21	Lawrence Blatt	Non-natural chemokine receptor ligands and methods of use thereof
BRPI0612947A2 (en)	2005-05-18	2010-12-07	Biogen Idec Inc	method for treating a fibrotic condition, method for treating pulmonary fibrosis, method for treating liver fibrosis, method for treating renal fibrosis, methods for treating a fibrotic disease and method for preventing a fibrotic disease
MX2008001166A (en)	2005-07-25	2008-03-18	Intermune Inc	Novel macrocyclic inhibitors of hepatitis c virus replication.
WO2007038264A2 (en)	2005-09-22	2007-04-05	Biogen Idec Ma Inc.	Gapr-1 methods
NZ591443A (en)	2005-09-22	2013-04-26	Intermune Inc	Granule formation of pirfenidone and pharmaceutically acceptable excipients
WO2007053658A1 (en)	2005-10-31	2007-05-10	Intermune, Inc.	Pirfenidone/toll-like receptor (tlr) agonist compositions and methods for using them to stimulate production of granulocyte colonizing stimulating factor (g-csf)
JP2009517390A (en)	2005-11-23	2009-04-30	インターミューンインコーポレイテッド	Methods for modulating stress-activated protein kinase systems
US20070203202A1 (en)	2005-12-02	2007-08-30	Robinson Cynthia Y	Methods of reducing adverse events associated with pirfenidone therapy
SG174050A1 (en)	2006-04-13	2011-09-29	Actelion Pharmaceuticals Ltd	Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
US20080003635A1 (en)	2006-06-12	2008-01-03	Intermune, Inc.	High Throughput Collagen Synthesis Assay
RU2008152171A (en)	2006-07-05	2010-08-10	Интермьюн, Инк. (Us)	NEW HEPATITIS C VIRAL REPLICATION INHIBITORS
AU2007328206B2 (en)	2006-12-04	2013-08-01	Promedior, Inc.	Conjoint therapy for treating fibrotic diseases
EP3053580B1 (en) *	2006-12-18	2021-06-30	InterMune, Inc.	Method of providing pirfenidone therapy to a patient
KR20100016045A (en)	2007-03-30	2010-02-12	센토코 오르토 바이오테크 인코포레이티드	Cxcl13 antagonists and their use for the treatment of inflammatory diseases
AU2007201663A1 (en)	2007-04-16	2008-10-30	Nautilus Biotech	Oral dosage formulations of protease resistant polypeptides
CA2583716A1 (en)	2007-04-18	2008-10-18	Nautilus Biotech	Oral dosage formulations of protease resistant polypeptides
US20080260820A1 (en)	2007-04-19	2008-10-23	Gilles Borrelly	Oral dosage formulations of protease-resistant polypeptides
US20080287508A1 (en)	2007-05-18	2008-11-20	Intermune, Inc.	Altering pharmacokinetics of pirfenidone therapy
CN102099036B (en)	2008-06-03	2015-05-27	英特芒尼公司	Compounds and methods for treating inflammatory and fibrotic disorders
US7635707B1 (en)	2008-11-10	2009-12-22	Intermune, Inc.	Pirfenidone treatment for patients with atypical liver function
US7566729B1 (en)	2008-11-10	2009-07-28	Intermune, Inc.	Modifying pirfenidone treatment for patients with atypical liver function

2009
- 2009-09-03 US US12/553,292 patent/US7635707B1/en active Active
- 2009-11-06 EP EP11001414.9A patent/EP2343070B1/en not_active Revoked
- 2009-11-06 ME MEP-2011-113A patent/ME01189B/en unknown
- 2009-11-06 ES ES11001414.9T patent/ES2525543T3/en active Active
- 2009-11-06 ES ES12166074.0T patent/ES2578715T3/en active Active
- 2009-11-06 DK DK09252572.4T patent/DK2191831T3/en active
- 2009-11-06 ES ES09252572T patent/ES2387421T3/en active Active
- 2009-11-06 PT PT110014149T patent/PT2343070E/en unknown
- 2009-11-06 RS RS20140692A patent/RS53721B1/en unknown
- 2009-11-06 DK DK11001414.9T patent/DK2343070T3/en active
- 2009-11-06 PL PL11001414T patent/PL2343070T3/en unknown
- 2009-11-06 SI SI200931071T patent/SI2343070T1/en unknown
- 2009-11-06 RS RS20110264A patent/RS51787B/en unknown
- 2009-11-06 EP EP12166074.0A patent/EP2500019B1/en not_active Revoked
- 2009-11-06 EP EP12166073A patent/EP2505199A1/en not_active Withdrawn
- 2009-11-06 EP EP09252572A patent/EP2191831B1/en active Active
- 2009-11-06 PT PT09252572T patent/PT2191831E/en unknown
- 2009-11-06 DE DE602009000986T patent/DE602009000986D1/en active Active
- 2009-11-06 PL PL09252572T patent/PL2191831T3/en unknown
- 2009-11-06 SI SI200930033T patent/SI2191831T1/en unknown
- 2009-11-06 AT AT09252572T patent/ATE503480T1/en active
- 2009-11-09 CN CN2009801444295A patent/CN102209543A/en active Pending
- 2009-11-09 TW TW098137907A patent/TWI419877B/en not_active IP Right Cessation
- 2009-11-09 MY MYPI2011002049A patent/MY159353A/en unknown
- 2009-11-09 AP AP2011005740A patent/AP2011005740A0/en unknown
- 2009-11-09 CA CA2709997A patent/CA2709997C/en active Active
- 2009-11-09 GE GEAP200912257A patent/GEP201706719B/en unknown
- 2009-11-09 EA EA201170669A patent/EA022482B1/en not_active IP Right Cessation
- 2009-11-09 PE PE2011000951A patent/PE20110683A1/en not_active Application Discontinuation
- 2009-11-09 AU AU2009313302A patent/AU2009313302B2/en not_active Revoked
- 2009-11-09 TW TW102123162A patent/TW201341361A/en unknown
- 2009-11-09 KR KR1020117012538A patent/KR101699501B1/en active IP Right Grant
- 2009-11-09 BR BRPI0921022A patent/BRPI0921022A2/en not_active IP Right Cessation
- 2009-11-09 JP JP2011535716A patent/JP2012508253A/en not_active Withdrawn
- 2009-11-09 CA CA2765402A patent/CA2765402A1/en not_active Abandoned
- 2009-11-09 WO PCT/US2009/063702 patent/WO2010054294A1/en active Application Filing
- 2009-11-09 MX MX2011004904A patent/MX2011004904A/en active IP Right Grant
- 2009-11-09 US US13/128,569 patent/US8609701B2/en active Active
2010
- 2010-08-16 AU AU2010212371A patent/AU2010212371B2/en not_active Revoked
- 2010-12-02 HK HK10111234.1A patent/HK1145138A1/en unknown
- 2010-12-02 HK HK13103299.7A patent/HK1176002A1/en not_active IP Right Cessation
- 2010-12-02 HK HK11107951.9A patent/HK1153668A1/en not_active IP Right Cessation
2011
- 2011-01-31 AU AU2011200385A patent/AU2011200385B2/en not_active Revoked
- 2011-03-31 ZA ZA2011/02411A patent/ZA201102411B/en unknown
- 2011-03-31 IL IL212064A patent/IL212064A/en active IP Right Grant
- 2011-04-29 CO CO11052726A patent/CO6382132A2/en not_active Application Discontinuation
- 2011-04-29 CL CL2011000966A patent/CL2011000966A1/en unknown
- 2011-05-05 TN TN2011000217A patent/TN2011000217A1/en unknown
- 2011-05-06 SV SV2011003897A patent/SV2011003897A/en unknown
- 2011-05-06 NI NI201100091A patent/NI201100091A/en unknown
- 2011-05-09 CU CU20110100A patent/CU20110100A7/en unknown
- 2011-05-10 EC EC2011011039A patent/ECSP11011039A/en unknown
- 2011-06-03 MA MA33917A patent/MA32880B1/en unknown
- 2011-06-28 HR HR20110478T patent/HRP20110478T1/en unknown
- 2011-06-28 CY CY20111100614T patent/CY1111595T1/en unknown
- 2011-07-15 SM SM201100030T patent/SMT201100030B/en unknown
- 2011-12-06 US US13/312,746 patent/US8592462B2/en active Active
2012
- 2012-07-06 JP JP2012152844A patent/JP2012193193A/en active Pending
2013
- 2013-11-12 US US14/078,186 patent/US20140073673A1/en not_active Abandoned
2014
- 2014-10-10 JP JP2014208600A patent/JP2015007132A/en active Pending
- 2014-12-08 CY CY20141101019T patent/CY1115862T1/en unknown
- 2014-12-17 HR HRP20141224AT patent/HRP20141224T1/en unknown
2015
- 2015-04-09 SM SM201500088T patent/SMT201500088B/en unknown
2016
- 2016-05-06 US US15/148,792 patent/US20160250198A1/en not_active Abandoned
- 2016-12-22 US US15/388,902 patent/US20170100381A1/en not_active Abandoned
2017
- 2017-08-04 US US15/669,552 patent/US20170333411A1/en not_active Abandoned
2018
- 2018-03-12 US US15/918,685 patent/US20180200242A1/en not_active Abandoned
- 2018-10-31 US US16/176,902 patent/US20190060299A1/en not_active Abandoned

Also Published As

Publication number	Publication date
GEP201706719B (en)	2017-08-25
US8592462B2 (en)	2013-11-26
PL2343070T3 (en)	2015-04-30
PT2343070E (en)	2015-01-14
JP2012508253A (en)	2012-04-05
EP2500019B1 (en)	2016-04-06
EP2191831B1 (en)	2011-03-30
KR101699501B1 (en)	2017-01-24
KR20110094295A (en)	2011-08-23
TWI419877B (en)	2013-12-21
AP2011005740A0 (en)	2011-06-30
CY1111595T1 (en)	2015-10-07
MY159353A (en)	2016-12-30
SI2191831T1 (en)	2011-07-29
ES2525543T3 (en)	2014-12-26
US20110263656A1 (en)	2011-10-27
NI201100091A (en)	2011-11-03
US20170100381A1 (en)	2017-04-13
PT2191831E (en)	2011-05-24
CA2709997C (en)	2012-03-27
ES2578715T3 (en)	2016-07-29
US20190060299A1 (en)	2019-02-28
DK2191831T3 (en)	2011-06-20
CO6382132A2 (en)	2012-02-15
SMT201500088B (en)	2015-05-05
US20160250198A1 (en)	2016-09-01
US20140073673A1 (en)	2014-03-13
CL2011000966A1 (en)	2011-08-19
MA32880B1 (en)	2011-12-01
EP2191831A1 (en)	2010-06-02
JP2012193193A (en)	2012-10-11
US7635707B1 (en)	2009-12-22
SI2343070T1 (en)	2015-01-30
HRP20141224T1 (en)	2015-03-27
PE20110683A1 (en)	2011-10-20
TN2011000217A1 (en)	2012-12-17
CU20110100A7 (en)	2012-01-31
CN102209543A (en)	2011-10-05
HRP20110478T1 (en)	2011-07-31
AU2010212371A1 (en)	2010-09-09
AU2011200385B2 (en)	2013-04-18
AU2009313302A1 (en)	2010-05-14
AU2009313302B2 (en)	2011-01-06
EP2343070B1 (en)	2014-10-15
ES2387421T3 (en)	2012-09-21
EP2505199A1 (en)	2012-10-03
US20120077850A1 (en)	2012-03-29
EP2343070A1 (en)	2011-07-13
ZA201102411B (en)	2014-06-25
HK1153668A1 (en)	2012-04-05
BRPI0921022A2 (en)	2015-12-29
SMT201100030B (en)	2011-09-09
ECSP11011039A (en)	2011-07-29
TW201020232A (en)	2010-06-01
DK2343070T3 (en)	2015-01-05
EA201170669A1 (en)	2011-10-31
EP2500019A1 (en)	2012-09-19
HK1145138A1 (en)	2011-04-08
EA022482B1 (en)	2016-01-29
RS51787B (en)	2011-12-31
MX2011004904A (en)	2011-06-16
CY1115862T1 (en)	2017-01-25
AU2010212371B2 (en)	2010-12-23
US8609701B2 (en)	2013-12-17
US20170333411A1 (en)	2017-11-23
HK1176002A1 (en)	2013-07-19
PL2191831T3 (en)	2011-09-30
SV2011003897A (en)	2011-08-09
RS53721B1 (en)	2015-04-30
AU2011200385A1 (en)	2011-02-17
US20180200242A1 (en)	2018-07-19
ATE503480T1 (en)	2011-04-15
DE602009000986D1 (en)	2011-05-12
CA2765402A1 (en)	2010-05-14
ME01189B (en)	2011-12-31
TW201341361A (en)	2013-10-16
WO2010054294A1 (en)	2010-05-14
IL212064A0 (en)	2011-06-30
CA2709997A1 (en)	2010-05-14
JP2015007132A (en)	2015-01-15

Publication	Publication Date	Title
IL212064A (en)	2016-06-30	Use of pirfenidone for the preparation of a medicament for the treatment of patients with atypical liver function
IL232251B (en)	2019-10-31	A pharmaceutical combination for use in the treatment of a diabetes type 2 patient
HK1217903A1 (en)	2017-01-27	Methods of administering pirfenidone therapy
IL211293A (en)	2016-08-31	Combination of agents for preparation of medication for tuberculosis therapy
IL223783B (en)	2018-06-28	Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
PT2611458T (en)	2016-12-16	Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
HK1184370A1 (en)	2014-01-24	Pharmaceutical combination for the treatment of pain
HK1167592A1 (en)	2012-12-07	Cycloundecadepsipeptide compounds and use of said compounds as a medicament
HK1202473A1 (en)	2015-10-02	Fluid-injection system for medical use in the vascular system of a patient
GB0715790D0 (en)	2007-09-26	Drug combination for the treatment of sialorrhoea
IL211267A (en)	2015-07-30	Oxadiazole derivatives and medicaments and use thereof for the treatment of diabetes
IL213770A (en)	2015-07-30	Use of a fibrate for the preparation of a medicament for the treatment of sleep apnea
GB2464112A9 (en)	2010-05-19	Mechanism for the inhibition of the needle/cannulamotion in disposable hypodermic syringes
PL382687A1 (en)	2008-12-22	Single-use medical syringe
GB0815390D0 (en)	2008-10-01	Syringe for medical use
PL384207A1 (en)	2009-07-06	Disposable medical syringe
SG10201601210YA (en)	2016-03-30	Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2

Legal Events

Date	Code	Title
2016-10-31	FF	Patent granted
2016-12-29	KB	Patent renewed
2019-11-28	KB	Patent renewed